Genfit SA and Ipsen SA Announce Positive Results from Phase III ELATIVE® Trial of Elafibranor in Patients with Primary Biliary Cholangitis Call Transcript
Good day, and welcome to the GENFIT Positive Top Line Data from Phase III ELATIVE trial of elafibranor in patients with Primary Biliary Cholangitis conference call. Today's call will be recorded.
At this time, I'd like to turn the call over to Stefanie Magner. Please go ahead.
Hello, everyone, and thanks for joining us on this conference call organized to follow up on the press release we published with Ipsen today on the elafibranor Phase III ELATIVE trial results. The press release can be accessed via our website at ir.genfit.com.
Joining me on the call today are Pascal Prigent, CEO; and Carol Addy, CMO.
Before we begin, I'd like to remind everyone that statements made during this conference call relating to the group's expected future performance, market potential business prospects, events or plans, including clinical plans, potential to obtain regulatory approvals, anticipated time lines for clinical development and study
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |